Z
Zhao Wang
Researcher at Centers for Disease Control and Prevention
Publications - 2
Citations - 2026
Zhao Wang is an academic researcher from Centers for Disease Control and Prevention. The author has contributed to research in topics: Randomized controlled trial & Adverse effect. The author has an hindex of 2, co-authored 2 publications receiving 1327 citations.
Papers
More filters
Journal ArticleDOI
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial.
Feng Cai Zhu,Yu-Hua Li,Xu Hua Guan,Li Hua Hou,Wen-Juan Wang,Jing Xin Li,Shi Po Wu,Bu Sen Wang,Zhao Wang,Lei Wang,Si Yue Jia,Hu Dachuan Jiang,Ling Wang,Tao Jiang,Yi Hu,Jin Bo Gou,Sha Bei Xu,Jun-Jie Xu,Xue-Wen Wang,Wei Wang,Wei Chen +20 more
TL;DR: A dose-escalation, single-centre, open-label, non-randomised, phase 1 trial of an Ad5 vectored COVID-19 vaccine expressing the spike glycoprotein of a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) strain to assess the safety, tolerability, and immunogenicity.
Journal ArticleDOI
Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial.
Feng Cai Zhu,Xu Hua Guan,Yu-Hua Li,Jian Ying Huang,Tao Jiang,Li Hua Hou,Jing Xin Li,Bei Fang Yang,Ling Wang,W J Wang,Shi Po Wu,Zhao Wang,Xiao Hong Wu,Jun Jie Xu,Zhe Zhang,Si Yue Jia,Bu Sen Wang,Yi Hu,Jing Jing Liu,Jun Zhang,Xiao Ai Qian,Qiong Li,Hong Xing Pan,Hu Dachuan Jiang,Peng Deng,Jin Bo Gou,Xue-Wen Wang,Xing Huan Wang,Wei Chen +28 more
TL;DR: The first randomised controlled trial for assessment of the immunogenicity and safety of a candidate non-replicating adenovirus type-5 (Ad5)-vectored COVID-19 vaccine, aiming to determine an appropriate dose of the candidate vaccine for an efficacy study, induced significant immune responses in the majority of recipients after a single immunisation.